Skin care research: Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.

Intelligent anti-aging skin care based on independent research

Lose wrinkles, keep your bank account!

Skin Care 101

Skin Care Basics

Skin Protection

Skin Biology

Biology of Aging

Ingredient Guide

Skin & Nutrition

Skin Conditions

Anti-Aging Treatments

Topical Actives

Wrinkle Fillers

Noninvasive

Invasive

Skin Care Smarts

Smart Choices

Best Practices

Find Good Skin Doc

Quick Tips

Freebie Finder

Reviews & Research

Product Reviews

Provider Reviews

Skin Care Research

Clinical Trials

How-To Infopacks

Skin Rejuvenation

DIY Skin Care

Skin & Nutrition

Eye Skin Care

Longevity In a Pill

Community & Misc

Forums

Polls & Surveys

News and Updates

Search

You are here: Skin Care Research >

Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.

Author: Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N, Botox Facial Aesthetics Study Team

Author affiliation: Cranley Clinic, London, United Kingdom. cranleyuk@aol.com

Publication date & source: 2005.03, Dermatol Surg., 31(3):257-62.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

BACKGROUND: Published evidence suggests that botulinum toxin type A (BTX-A) is an effective treatment for crow's feet. However, few dose-ranging studies have been performed. OBJECTIVES: To assess the safety and efficacy of a single treatment with one of four doses of BTX-A (Botox/Vistabel, Allergan Inc) compared with placebo for the improvement of crow's feet. METHODS: Subjects received a single bilateral treatment of 18, 12, 6, or 3 U of BTX-A or placebo injected into the lateral aspect of the orbicularis oculi muscle (parallel-group, double-blind design). Investigators and subjects rated crow's feet severity at maximum smile on day 7 and at 30-day intervals from days 30 to 180. RESULTS: As observed by both investigators and subjects, all doses of BTX-A resulted in improvements in crow's feet severity when compared with placebo. A dose-dependent treatment effect for efficacy was observed, with higher doses having an increased magnitude and duration of effect. However, a clear differentiation between the 18 U and 12 U doses was not apparent. Few adverse events were reported, with no statistically significant differences between BTX-A and placebo in the incidence of subjects experiencing adverse events. CONCLUSION: BTX-A is safe and effective in decreasing the severity of crow's feet, with 12 U per side suggested as the most appropriate dose.

Indexes of Skin Care Research Abstracts
by Subject Category	Most Recent

-- advertisements --